The company’s third pipeline product, CTB-02, is a cocktail therapy with novel combinations discovered through Cothera’s i-CR® Platform. CTB-02 targets colon cancer and non-small cell lung cancer with pan-KRAS mutations. There are currently no approved targeted therapies for KRAS-mutant colorectal cancer, resulting in huge clinical unmet needs. In CDX and PDX animal experiments, CBT-02 demonstrated powerful inhibitory effect not only on KRAS G12C-mutated colorectal cancer, but also on cancers with other KRAS mutations.
The CTB-02 program is currently in Phase 1b clinical development.
